Question 1

What are the potential benefits of adding lenvatinib to my treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study clinical trial (NCT04716933). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this trial compare to other treatment options available for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study clinical trial (NCT04716933). Contact the study team or your healthcare provider for specific answers.

Question 3

What side effects should I expect from the treatments in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study clinical trial (NCT04716933). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to visit the clinic if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study clinical trial (NCT04716933). Contact the study team or your healthcare provider for specific answers.

Question 5

What are the eligibility criteria for this trial, and do I meet them?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study clinical trial (NCT04716933). Contact the study team or your healthcare provider for specific answers.

Question 6

How will my health be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study clinical trial (NCT04716933). Contact the study team or your healthcare provider for specific answers.

What this study is about